Japanese Encephalitis-Pipeline Review, H1 2015

Japanese Encephalitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6752IDB
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Japanese Encephalitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Japanese Encephalitis-Pipeline Review, H1 2015', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Japanese Encephalitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Japanese Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Japanese Encephalitis Overview 7

Therapeutics Development 8

Pipeline Products for Japanese Encephalitis-Overview 8

Pipeline Products for Japanese Encephalitis-Comparative Analysis 9

Japanese Encephalitis-Therapeutics under Development by Companies 10

Japanese Encephalitis-Therapeutics under Investigation by Universities/Institutes 11

Japanese Encephalitis-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Japanese Encephalitis-Products under Development by Companies 15

Japanese Encephalitis-Products under Investigation by Universities/Institutes 16

Japanese Encephalitis-Companies Involved in Therapeutics Development 17

Arbovax, Inc. 17

Indian Immunologicals Limited 18

Panacea Biotec Limited 19

Sanofi 20

Vaxine Pty Ltd 21

Zydus Cadila Healthcare Limited 22

Japanese Encephalitis-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

FDX-000-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

encephalitis vaccine-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Japanese encephalitis B vaccine-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Japanese encephalitis vaccine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Japanese encephalitis vaccine-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Japanese encephalitis vaccine-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Japanese encephalitis vaccine-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Japanese encephalitis vaccine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Japanese encephalitis vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Japanese encephalitis vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Japanese encephalitis vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Small Molecule to Inhibit NS5 for Dengue and Flavivirus Infections-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Japanese Encephalitis-Recent Pipeline Updates 43

Japanese Encephalitis-Dormant Projects 44

Japanese Encephalitis-Discontinued Products 45

Japanese Encephalitis-Product Development Milestones 46

Featured News & Press Releases 46

Dec 10, 2012: Sanofi Pasteur Launches Imojev First Single-dose Vaccine against Japanese Encephalitis In Australia 46

Jun 29, 2007: Discontinuation of Japanese encephalitis vaccine 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for Japanese Encephalitis, H1 2015 8

Number of Products under Development for Japanese Encephalitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Comparative Analysis by Unknown Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Japanese Encephalitis-Pipeline by Arbovax, Inc., H1 2015 17

Japanese Encephalitis-Pipeline by Indian Immunologicals Limited, H1 2015 18

Japanese Encephalitis-Pipeline by Panacea Biotec Limited, H1 2015 19

Japanese Encephalitis-Pipeline by Sanofi, H1 2015 20

Japanese Encephalitis-Pipeline by Vaxine Pty Ltd, H1 2015 21

Japanese Encephalitis-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Japanese Encephalitis Therapeutics-Recent Pipeline Updates, H1 2015 43

Japanese Encephalitis-Dormant Projects, H1 2015 44

Japanese Encephalitis-Discontinued Products, H1 2015 45

List of Figures

Number of Products under Development for Japanese Encephalitis, H1 2015 8

Number of Products under Development for Japanese Encephalitis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Arbovax, Inc.

Indian Immunologicals Limited

Panacea Biotec Limited


Vaxine Pty Ltd

Zydus Cadila Healthcare Limited

Japanese Encephalitis Therapeutic Products under Development, Key Players in Japanese Encephalitis Therapeutics, Japanese Encephalitis Pipeline Overview, Japanese Encephalitis Pipeline, Japanese Encephalitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com